1. Home
  2. NUVL vs VMI Comparison

NUVL vs VMI Comparison

Compare NUVL & VMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.82

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Valmont Industries Inc.

VMI

Valmont Industries Inc.

HOLD

Current Price

$475.33

Market Cap

8.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
VMI
Founded
2017
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.1B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
VMI
Price
$100.82
$475.33
Analyst Decision
Strong Buy
Buy
Analyst Count
15
4
Target Price
$135.00
$462.33
AVG Volume (30 Days)
497.6K
115.3K
Earning Date
02-27-2026
02-17-2026
Dividend Yield
N/A
0.58%
EPS Growth
N/A
N/A
EPS
N/A
11.66
Revenue
N/A
$4,103,136,000.00
Revenue This Year
N/A
$1.86
Revenue Next Year
N/A
$4.12
P/E Ratio
N/A
$40.09
Revenue Growth
N/A
1.23
52 Week Low
$55.54
$250.07
52 Week High
$113.02
$487.58

Technical Indicators

Market Signals
Indicator
NUVL
VMI
Relative Strength Index (RSI) 49.64 67.46
Support Level $98.65 $463.43
Resistance Level $106.57 $487.58
Average True Range (ATR) 4.46 12.28
MACD -0.29 0.95
Stochastic Oscillator 47.36 72.02

Price Performance

Historical Comparison
NUVL
VMI

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About VMI Valmont Industries Inc.

Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.

Share on Social Networks: